Higher ASA Class Not Tied to 30-Day Morbidity in Spinal Surgery

This article originally appeared here.
Share this content:
Higher ASA Class Not Tied to 30-Day Morbidity in Spinal Surgery
Higher ASA Class Not Tied to 30-Day Morbidity in Spinal Surgery

FRIDAY, Feb. 17, 2017 (HealthDay News) -- For patients undergoing single-level elective anterior cervical discectomy and fusion (SLE-ACDF), higher American Society of Anesthesiologists (ASA) classification is not associated with 30-day morbidity, according to a study published in the March issue of The Spine Journal.

Seokchun Lim, M.D., from the Henry Ford Hospital in Detroit, and colleagues selected 6,148 patients who underwent SLE-ACDF between 2011 and 2013 from the American College of Surgeons National Surgical Quality Improvement Program database. The authors assessed the predictive value of ASA classification system on 30-day morbidity.

The researchers found that the incidence of comorbidities and postoperative complications was increased for patients in the ASA >II cohort. In multivariable analyses within a cohort of 1,628 propensity score-matched pairs, ASA class >II was not significantly associated with 30-day outcomes: any complications (odds ratio [OR], 0.82; 95 percent confidence interval [CI], 0.48 to 1.41); pneumonia (OR, 1.22; 95 percent CI, 0.33 to 4.56); unplanned intubation (OR, 1.49; 95 percent CI, 0.41 to 5.36); ventilator >48 hours (OR, 5.92; 95 percent CI, 0.69 to 50.96); catastrophic outcome (OR, 1.02; 95 percent CI, 0.39 to 2.71); and airway complication (OR, 2.21; 95 percent CI, 0.67 to 7.29).

"Although we did not detect associations between ASA class >II and adverse 30-day outcomes following SLE-ACDF, imprecision of estimates precludes definitive inferences," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »